Results 141 to 150 of about 1,587,143 (318)

Current pharmacological treatment of idiopathic inflammatory myopathies [PDF]

, 2016
The idiopathic inflammatory myopathies are uncommon and heterogeneous disorders. Their classification is based on distinct clinicopathologic features.
Alves, SC, Fasano, S, Isenberg, DA
core   +1 more source

New insights into applications of base editor in hereditary disorders

Interdisciplinary Medicine, EarlyView.
Abstract Hereditary disorders are a group of diseases caused by genetic mutations or chromosomal variations. Although the incidence of each genetic disorder is relatively low, patients affected by the disease generally experience a range of severe symptoms, including blindness, disability, and even premature death. In addition, the available treatments
Maoping Cai, Linhui Zhang, Liqing Li, Yue Liu, Canbin Lv, Yan Shi, Jianyuan Zhao, Dingwei Ye, Yuanyuan Qu   +8 more
wiley   +1 more source

Rituximab in the treatment of inflammatory myopathies: a review [PDF]

, 2017
Several uncontrolled studies have encouraged the use of rituximab (RTX) in patients with myositis. Unfortunately, the first placebo-phase trial to assess the efficacy of RTX in refractory myositis did not show a significant difference between the two ...
Fasano, S, Gordon, P, Hajji, R, Isenberg, DA, Loyo, E   +4 more
core  

POS0490 USEFULNESS OF MHC-II IMMUNO-STAINING ON MUSCLE BIOPSIES IN IDIOPATHIC INFLAMMATORY MYOPATHIES [PDF]

, 2022
M Robert, L. Lessard, T. Fenouil, A. Hot, T. Laumonier, A. Bouche, B. Chazaud, N. Streichenberger, L. Gallay   +8 more
openalex   +1 more source

EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report

RMD Open, 2017
Objective To describe the methodology used to develop new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIMs) and their major subgroups. Methods An international, multidisciplinary group of myositis experts produced a
M. Bottai, A. Tjärnlund, G. Santoni, V. Werth, C. Pilkington, M. de Visser, L. Alfredsson, A. Amato, R. Barohn, M. Liang, J. Singh, R. Aggarwal, S. Arnardóttir, H. Chinoy, R. Cooper, K. Dankó, M. Dimachkie, B. Feldman, I. García-De La Torre, P. Gordon, Taichi Hayashi, J. Katz, H. Kohsaka, P. Lachenbruch, B. Lang, Yu-hui Li, C. Oddis, Marzena Olesinka, A. Reed, L. Rutkowska-Sak, H. Sanner, A. Selva-O’Callaghan, Yeong Wook Song, J. Vencovský, S. Ytterberg, F. Miller, L. Rider, I. Lundberg   +37 more
semanticscholar   +1 more source

Dermatomyositis Like Presentation of Anti‐HMGCR Immune Mediated Necrotising Myopathy

JEADV Clinical Practice, EarlyView.
ABSTRACT Extramuscular manifestations of anti‐3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR) immune‐mediated necrotising myopathy (IMNM) are rare and often overlooked because they are overshadowed by predominant muscular symptoms. The types of cutaneous manifestations can be numerous.
Lionel Leblanc, Lyna Mtimet, Louis Wolff, Evelyne Berlingin, Bruno Couturier   +4 more
wiley   +1 more source

Polymyositis and dermatomyositis – challenges in diagnosis and management

Journal of Translational Autoimmunity, 2019
Polymyositis (PM) and dermatomyositis (DM) are different disease subtypes of idiopathic inflammatory myopathies (IIMs). The main clinical features of PM and DM include progressive symmetric, predominantly proximal muscle weakness.
Shu-Han Yang, Christopher Chang, Zhe-Xiong Lian   +2 more
doaj   +1 more source

Az anti-Jo-1-pozitív antiszintetáz szindróma jellegzetességei gondozott betegeink alapján [PDF]

, 2016
Absztrakt Bevezetés: Az idiopathiás inflammatorikus myopathiák a proximális végtagizmok szimmetrikus gyengeségével jellemezhető szisztémás autoimmun betegségek.
Bodoki, Levente, Dankó, Katalin, Griger, Zoltán, Hodosi, Katalin, Nagy-Vincze, Melinda, Szabó, Katalin   +5 more
core   +1 more source

Muscle Ultrasound in Inflammatory Myopathies: A Critical Review

Journal of Rheumatic Diseases and Treatment, 2019
Muscle ultrasonography is an upcoming tool in the evaluation of neuromuscular disorders. It is easily applicable in multiple clinical settings, has no contraindications, and provides a cost-effective alternative to other imaging modalities such as MRI ...
Leeuwenberg Kristofoor E, Albayda Jemima
semanticscholar   +1 more source

Loganin, an Iridoid Glycoside, Alleviates Paclitaxel‐Induced Skeletal Muscle Toxicity by Enhancing Mitochondrial Function, Boosting Antioxidant Defenses, and Reducing Cellular Senescence

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Mitochondrial dysfunction and energy imbalance caused by chemotherapy are key contributors to skeletal muscle atrophy, which severely impacts the quality of life in cancer patients. Paclitaxel, a commonly used chemotherapeutic agent, is known to promote muscle wasting and cellular senescence, largely by impairing mitochondrial function.
Yu‐Fan Chuang, Cai‐Rong Wu, Wan‐Hsuan Chang, Ying‐Jung Su, Hung‐Te Hsu, Fan‐Li Lin, Yi‐Ching Lo   +6 more
wiley   +1 more source